DHMRI and Metabolon Announce Strategic Partnership
News Sep 04, 2013
The David H. Murdock Research Institute (DHMRI) and Metabolon, Inc. have announced that they have entered into a strategic agreement to align metabolomics research services.
Metabolon is a pioneering leader in discovery metabolomics and specializes in rapidly assessing metabolism in biological samples to quickly identify prospective biomarkers and to understand metabolic effects of treatments, interventions, nutritionals, etc.
The agreement complements DHMRI’s mass spectrometry and NMR-based metabolomics services through access to Metabolon’s industry-leading high-throughput biomarker discovery and profiling platform which provides an extensive, untargeted, broad metabolite survey of more than 4000 biochemicals.
“This agreement leverages the strengths of our organizations to best serve DHMRI collaborators to understand metabolism and ultimately answer key research questions and deliver healthy food products for consumers. We have worked extensively in food science and nutrition and recognize that our combined resources are indeed complementary. DHMRI is a center of excellence in nutrition research and we are delighted to do our part to meet their growing needs,” says Chris Bernard, Senior Vice President of Sales & Marketing for Metabolon.
DHMRI is an established not-for-profit research institute that provides flexible, client-focused research services to academia, government and industry collaborators.
This agreement, consistent with the DHMRI’s collaborative approach to scientific inquiry, provides partners with additional resources for metabolomics.
Metabolon’s global metabolomic approach can pinpoint active pathways which can be further interrogated by targeted and or customized approaches offered by the DHMRI Metabolomics team.
“We are excited to broaden the breadth of services offered by the DHMRI to our collaborators. The benefits stemming from the collective knowledge of our organizations will be readily realized by researchers, companies and consumers,” said Steve Lommel, Ph.D., Interim President, David H. Murdock Research Institute.
Azafaros B.V. Secures Seed Funding to Develop New Treatments in Rare Metabolic DisordersNews
Company to address unmet medical needs in the field of rare metabolic disorders.READ MORE
Endomag Raises $10 Million USD (£8M GBP) to Establish a New Standard of Breast Cancer CareNews
Investment will be used to expand commercial activity.READ MORE
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
15th International Conference and Exhibition on Metabolomics & Systems
Apr 29 - Apr 30, 2019